Depression is one of the most prevalent mental health disorders, affecting around one in six adults in the UK. Current treatments include a combination of self-help, talking therapies and medication, as well as digital therapeutics. These are software-based therapies that have undergone clinical trials and regulatory review. Cognitive behavioural therapy (CBT)-based digital therapeutics have been shown to be an effective treatment for depression.
Otsuka, a pharmaceutical company, is developing a new digital treatment for depression: ‘CARE for MDD’ is digital therapeutic app that delivers a standalone six-week programme based on a new cognitive task combined with CBT-based psychotherapy lessons. It has the UK Conformity Assessed (UKCA) mark.
HIOTV conducted a feasibility study and engaged with key stakeholders in the NHS depression pathway to assess the clinical need, perceived potential benefits, acceptability and barriers to adoption of the app for people with moderate depression.
